ArticleJournal of thrombosis and thrombolysis2026
Toward platelet-count-adaptive anticoagulation in cancer thrombocytopenia: a standards-first, equity-aware proposal.
Article in Journal of thrombosis and thrombolysis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer-associated thrombosis (CAT) with thrombocytopenia (TP) poses concurrent risks of bleeding and recurrence. Guidance is fragmented by nonuniform platelet thresholds, tumor-context effects on agent choice, and scarce prospective data for DOACs specifically in TP. We outline a platelet-count-adaptive framework: (i) standardized platelet bands linked to dose/agent actions; (ii) tumor-biology-aware selection; (iii) transfusion-sparing triggers; and (iv) a core outcome set that indexes events to time spent within platelet bands ("platelet-adjusted bleeding rate"). The schema is evidence-aligned, feasible in resource-constrained settings, and offers testable standards for pragmatic trials. Translating recent syntheses into implementable, equity-aware standards can reduce unwarranted variation and accelerate learning across diverse care settings.
Indexed as
Identifiers
41575725What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.